Beta blockers are established treatments for many cardiovascular conditions and are indicated for the management of heart failure (HF), coronary artery disease (CAD), cardiac arrhythmias, hypertension, aortic dissection, and portal hypertension (Farzam, 2023). Beta blockers are disease-modifying medications that are mainstay treatments for HF with reduced ejection fraction (HFrEF) (Paolillo, 2021). Consequently, the most recent European guidelines for HFrEF management recommend beta blockers as first-line therapies in patients who are clinically stable and euvolemic (McDonagh, 2021). In patients with acute HF, beta blockers should be initiated in hospital settings after the patient is hemodynamically stabilized (McDonagh, 2021). However, to achieve full prognostic benefits, beta-blocker administration needs to be titrated to the maximum tolerable dose (Paolillo, 2021). Despite guideline recommendations and the potential benefits of these agents, physicians underuse beta blockers for patients with HFrEF who have other comorbidities even when these are not contraindications to beta-blocker use (Paolillo, 2021).  Therefore, the presence of such comorbidities should not limit the use of beta blockers in patients with HFrEF. Beta blockers are also considered first-line treatment to control heart rate and relieve CAD due to their anti-ischemic effects (Knuuti, 2020). Studies also show that early and long-term beta-blocker treatment reduces death and reinfarction rates in patients with CAD (e.g. Kim, 2020) reduces all-cause mortality in CAD and diabetes mellitus (Chen, 2023). Therefore, this podcast highlights to healthcare professionals the need to understand the appropriate position of beta blockers in order to treat patients with CAD who will benefit from their well-established pharmacological effects.